Pardes Biosciences, Inc.
Pardes Biosciences, Inc. (PRDS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
prds · stock forecast · 3 analysts (3M) · FMP · updated Oct 11, 2024
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Hold
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.16
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PRDS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-07-18 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2023-07-17 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2023-04-04 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2023-04-03 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2023-03-15 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2023-03-14 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2023-01-27 | SVB Leerink | Maintains | Outperform→Outperform |
| 2023-01-26 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-12-13 | JMP Securities | Maintains | Market Outperform→Outperform |
| 2022-08-16 | SVB Leerink | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Pardes Biosciences, Inc. (PRDS) stock. Of the recent 13 rating actions, 0 were upgrades and 4 were downgrades. 3 analysts currently cover PRDS.
Analyst Recommendation Trends
PRDS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast PRDS EPS of $— for the current fiscal year, based on estimates from 0 analysts. The PRDS revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PRDS stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PRDS price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
Pardes Biosciences, Inc. trades on NASDAQ under the ticker PRDS. The PRDS stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
PRDS forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month PRDS price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.16.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.